Bioelectronics Corp (BIEL)

[srinsocal]

$30 Million for Trials, Bioelectronic Device in Rheumatoid Arthritis

SetPoint Medical rounded up $30 million in its series D round, which will drive the clinical development of its bioelectronic treatments for chronic, inflammatory illnesses and bankroll a phase 2 trial of a bioelelectronic device in rheumatoid arthritis.

"Existing investors, including New Enterprise Associates, GlaxoSmithKline, Boston Scientific and Medtronic, participated in the financing. Valencia, California-based SetPoint previously raised $15 million in series C funding.

Bioelectronic therapies, based on implantable devices that stimulate the body to heal itself from disease, are increasingly being looked to as alternative treatments for inflammatory diseases, which often have limited treatment options.

SetPoint’s bioelectronic platform is designed to stimulate the body’s natural Inflammatory Reflex and trigger an anti-inflammatory effect, the company says. Bioelectronics could be used to elicit biochemical changes in the body that are typically brought about by drugs.
***************************************************
How about an Anti-Inflammatory Bioelectronic Device that does not require Implant Surgery.

https://www.fiercebiotech.com/medtech/setpoint-medical-nabs-30m-for-bioelectronics-rheumatoid-arthritis-trial